The US approval of Biogen and Eisai’s Alzheimer’s treatment Aduhelm (aducanumab) may have proven controversial in the biopharma sector, but it has given one small Swiss biotech, Neurimmune, a long-awaited breakthrough moment.
The University of Zurich spin-out discovered aducanumab back in 2004 and licensed the monoclonal antibody to Biogen three years later
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?